CN Stock MarketDetailed Quotes

301393 Suzhou Highfine Biotech

Watchlist
  • 43.65
  • -1.49-3.30%
Market Closed Nov 15 15:00 CST
4.71BMarket Cap40.49P/E (TTM)

About Suzhou Highfine Biotech Company

The company was founded in 2003 and is a high-tech enterprise providing specialty raw materials for global pharmaceutical R&D and API manufacturers. The company focuses on R&D, production and sales of peptide synthesis reagents. The main products are: peptide synthesis reagents, general-purpose molecular blocks, protein reagents, liposomes and lipid nanoparticle pharmaceutical reagents. Corporate honors: Suzhou High-tech Zone Gazelle Enterprise, 2018 High-tech Zone Advanced Unit for Science and Technology Innovation, Specialized and New Small and Medium Enterprises, etc.

Company Profile

Short Name-A昊帆生物
Symbol-A301393
Company NameSuzhou Highfine Biotech Co., Ltd.
Listing DateJul 12, 2023
Issue Price67.68
Shares Offered27.00M share(s)
FoundedDec 2, 2003
Legal Representativeyong zhu
General Manageryong zhu
Secretaryshengjun dong
Accounting FirmZhongtianyun Certified Public Accountants Co., Ltd. (Special General Partnership)
Securities Representativeyan fan
Legal CounselShanghai Guangfa Law Firm
Employees176
Phone0512-65399366
Office AddressNo.1 Changting Road, Suzhou High-tech Zone, Jiangsu
Zip Code215151
Registered AddressNo.1 Changting Road, Suzhou High-tech Zone, Jiangsu
Fax0512-68056883
Emailir@highfine.com
Business License320512000022224
BusinessR&D, production and sales: biosynthetic reagents and related reagents; provision of related technical services; sales: pharmaceutical intermediates and related products; import and export of commodities and technology (with the exception of goods and technologies operated by state-limited enterprises or prohibited from being imported or exported). (For projects requiring approval according to law, business activities can only be carried out after approval by the relevant departments)

Company Executives

  • Name
  • Position
  • Salary
  • yong zhu
  • Chairman, Directors, General Manager, Nomination Committee Members, Chairman of the Strategy Committee
  • 642.10K
  • minjie lv
  • Directors, Deputy General Manager, Member of the Remuneration and Assessment Committee
  • 543.40K
  • qizhu sun
  • Directors
  • 475.10K
  • jie xu
  • Directors, Deputy General Manager, Strategy Committee Member
  • 560.80K
  • yu luo
  • Directors
  • 607.30K
  • xuegen lu
  • Directors, Deputy General Manager
  • 528.50K
  • jiahui yu
  • Independent Directors, Member of the Remuneration and Assessment Committee, Audit Committee Member, Chairman of the Nomination Committee
  • 30.00K
  • xiaoping xu
  • Independent Directors, Chairman of the Remuneration and Assessment Committee, Strategy Committee Member, Audit Committee Member
  • 72.00K
  • qing wang
  • Independent Directors, Nomination Committee Members, Chairman of the Audit Committee
  • 72.00K
  • shengjun dong
  • Board Secretary, Deputy General Manager
  • 455.90K
  • yan fan
  • Securities Affairs Representative
  • --
  • haoyi sun
  • Chairman of the Supervisory Board, Auditors
  • 493.50K
  • jinfeng li
  • Auditors
  • 304.40K
  • xiaoyan wang
  • Head of Finance
  • 259.40K
  • yifan chen
  • Head of the Internal Audit Department
  • --
  • xiangguo cai
  • Employee Supervisors
  • 421.80K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
CN
Overall
Symbol
Latest Price
% Chg

No Data